| |
| |
|
|
A BILL TO BE ENTITLED
|
|
|
AN ACT
|
|
|
relating to health benefit plan coverage for ovarian cancer testing |
|
|
and screening. |
|
|
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|
|
SECTION 1. Section 1370.003(b), Insurance Code, is amended |
|
|
to read as follows: |
|
|
(b) Coverage required under this section includes at a |
|
|
minimum: |
|
|
(1) a CA 125 blood test; [and] |
|
|
(2) a conventional Pap smear screening or a screening |
|
|
using liquid-based cytology methods, as approved by the United |
|
|
States Food and Drug Administration, alone or in combination with a |
|
|
test approved by the United States Food and Drug Administration for |
|
|
the detection of the human papillomavirus; and |
|
|
(3) any other test or screening approved by the United |
|
|
States Food and Drug Administration for the detection of ovarian |
|
|
cancer. |
|
|
SECTION 2. Section 1370.003, Insurance Code, as amended by |
|
|
this Act, applies only to a health benefit plan delivered, issued |
|
|
for delivery, or renewed on or after January 1, 2022. A health |
|
|
benefit plan delivered, issued for delivery, or renewed before |
|
|
January 1, 2022, is governed by the law as it existed immediately |
|
|
before the effective date of this Act, and that law is continued in |
|
|
effect for that purpose. |
|
|
SECTION 3. This Act takes effect September 1, 2021. |